The invention relates to a method and intermediate compounds for the preparation of menaquinone MK-7. The method for the preparation of menaquinone MK-7 is characterized in that, it comprises coupling of a compound of formula (11) with a compound of formula (17) in the presence of a base, to obtain a compound of formula (18), which is subjected to desulfonylation reaction in the presence of a palladium catalyst, to obtain a compound of formula (19), which is subjected to oxidation reaction, to obtain menaquinone MK-7. The invention also relates to compound (8), preferably in a crystalline form, which is a convenient intermediate compound for the preparation of menaquinone MK-7.

The invention relates to a method and intermediate compounds for the preparation of menaquinone MK-7. The method for the preparation of menaquinone MK-7 is characterized in that, it comprises coupling of a compound of formula (11) with a compound of formula (17) in the presence of a base, to obtain a compound of formula (18), which is subjected to desulfonylation reaction in the presence of a palladium catalyst, to obtain a compound of formula (19), which is subjected to oxidation reaction, to obtain menaquinone MK-7. The invention also relates to compound (8), preferably in a crystalline form, which is a convenient intermediate compound for the preparation of menaquinone MK-7.

The present disclosure relates to the synthesis of Vitamin K2 bearing varying prenyl side chains. The synthesis comprises the reaction of phenyl sulfone of tert-butyl dimethyl silyl (TBDMS) protected mono prenyl menadiol with prenyl halides bearing varying prenyl units in the presence of the phase transfer catalyst followed by reductive desulphonation to yield TBDMS ether of Vitamin K2. The TBDMS ether is then oxidized in the presence of chromium trioxide and periodic acid to yield the corresponding Vitamin K2.

The present disclosure relates to the synthesis of Vitamin K2 bearing varying prenyl side chains. The synthesis comprises the reaction of phenyl sulfone of tert-butyl dimethyl silyl (TBDMS) protected mono prenyl menadiol with prenyl halides bearing varying prenyl units in the presence of the phase transfer catalyst followed by reductive desulphonation to yield TBDMS ether of Vitamin K2. The TBDMS ether is then oxidized in the presence of chromium trioxide and periodic acid to yield the corresponding Vitamin K2.